Abstract
PURPOSE: Moxifloxacin 8-methoxy-quinolone has an excellent in virto activity against common gram positive, gram negative and intracellular respiratory tract pathogens. Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is characterized by increase in cough and worsening of dyspnoea due to, in some cases, bacterial infection. There is always a need to develop first line antimicrobial agents that cover major respiratory pathogens, with low potential to select for resistance, favorable safety and tolerability profiles, and convenient dosing regimen. The purpose of this study was to evaluate the outcome of treating AECOPD patients empirically with 400 mg moxifloxacin single oral dose for 5 and 10 days.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
